Pharma / Biotech

Development an UPLC-ESI-Orbitrap MS method for determination of xanthopurpurin in rat plasma and its application to pharmacokinetic study.



Related Articles

Development an UPLC-ESI-Orbitrap MS method for determination of xanthopurpurin in rat plasma and its application to pharmacokinetic study.

Biomed Chromatogr. 2020 Apr 04;:e4838

Authors: Han DE, Shi Y, Tian P, Wei H, Miao M, Li XM

Abstract
A rapid and sensitive method was developed and validated for the quantitative determination of xanthopurpurin (XPP) in rat plasma by UPLC-ESI-Orbitrap mass spectrometry (UPLC-ESI-Orbitrap MS). XPP inhibits IgE production and prevents peanut-induced anaphylaxis. The XPP and emodin (IS) were determined in negative ion mode with m/z 239.0350→211.0400 and 269.0455→241.0507, respectively. The separation process was achieved by ACQUITY UPLC HSS T3 column (2.1 mm × 100 mm, 1.8 μm, Waters Corp., Milford, MA, USA) with acetonitrile and 0.1% formic acid in water (85:15). The linear range was 0.5 ~ 100 ng/mL, and the correlation coefficient (r2 ) was greater than 0.993. The inter-day and intra-day precision was measured within an acceptable range of 15%. The extraction recovery and matrix effect were 78.9 to 87.2% and 94.3 to 98.5%, respectively. Under different conditions, the XPP was stable in the range of 5.6 ~ 10.6%. This method has been successfully applied to study the pharmacokinetics of XPP with oral dose of 10.0 mg/kg and intravenous dose of 2.0 mg/kg in rats, respectively. The absolute oral bioavailability of XPP was 4.6%.

PMID: 32246852 [PubMed – as supplied by publisher]

Source link






Related posts

Ketamine Does Not Prevent Chronic Pain in Acute Trauma Patients

Newsemia

clinical pharmacology; +136 new citations

Newsemia

journal pharmacology; +3259 new citations

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy